Instrument NameSanofi-Aventis S.A. ADRInstrument Symbol(SNY-Q)

Instrument ExchangeNASDAQ

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection

The biotech continues to earn important wins, but is it enough?

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading market shares in growing categories.

Investors found something to like about the company's recent round of clinical trials for a key pipeline medication.

Don't be too quick to jump on the Wall Street bandwagon.

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data...

Its been a good year so far for the biotech, but how long can it keep the momentum going?

SNY earnings call for the period ending June 30, 2024.

Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities.

We will know a lot more about the vaccine maker's long-term prospects in 12 months.

Shares of the vaccine maker are trading up 230% this year.

The integration of AI and healthcare is well underway.

These pharma and biotech players could become long-term winners.

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

The vaccine maker's recovery story is looking brighter.

The biotech still hasn't lost momentum.

Sanofi believes in Novavax's vaccine strengths...

Novavax shares have soared and plummeted in recent years.

Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.

A cloud of doubt hanging over the company just gave way to some sunshine.

Sanofi will take a 4.9% stake in the U.S. drugmaker for $70-million. That values Novavax at about $1.4-billion, nearly double its market capitalization of about $628-million as of Thursday

Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib.

It pays to develop novel medicines for life-threatening illnesses.